New Drug Approvals Archive

New Drug Approvals: August 2008

August 1
Cardene (nicardipine)

New Formulation Approved: July 31, 2008

FDA Approves New Cardene Formulation
 
August 4
Exforge (amlodipine and valsartan)

New Indication Approved: July 23, 2008

Single-Pill Combinations Diovan HCT and Exforge Approved in US as First-Line Treatments for High Blood Pressure
 
August 4
Cleviprex (clevidipine butyrate) Injectable Emulsion

Date of Approval: August 1, 2008

Company: The Medicines Company

Treatment for Hypertension

Cleviprex is an intravenous, ultrashort-acting calcium channel blocker under development for the treatment of severely elevated blood pressure in the hospital setting when oral therapy is not feasible or desirable.

The Medicines Company’s Cleviprex Receives FDA Approval
 
August 11
Viread (tenofovir disoproxil fumarate)

New Indication Approved: August 11, 2008

U.S. Food and Drug Administration Approves Viread for Chronic Hepatitis B in Adults
 
August 15
Xenazine (tetrabenazine)

Date of Approval: August 15, 2008

Company: Prestwick Pharmaceuticals, Inc.

Treatment for Huntington’s Chorea

Xenazine (tetrabenazine) is a selective and reversible centrally-acting dopamine depleting drug indicated for the treatment of chorea associated with Huntington's disease.

Xenazine (Tetrabenazine) Approved by FDA for Patients with Chorea Associated with Huntington's Disease
 
August 21
Vidaza (azacitidine)

New Indication Approved: August 20, 2008

Vidaza Receives Expanded FDA Approval to Include Overall Survival in Higher-Risk MDS
 
August 22
Nplate (romiplostim)

Date of Approval: August 22, 2008

Company: Amgen Inc.

Treatment for Idiopathic (Immune) Thrombocytopenic Purpura

Nplate (romiplostim) is a thrombopoietin mimetic peptibody for the treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP).

FDA Approves Nplate for Long-Term Treatment of Adult Chronic ITP
 
August 25
Aloxi (palonosetron)

New Dosage Form Approved: August 22, 2008

FDA Approves Aloxi (palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
 
August 26
Novolog Mix (insulin aspart and insulin aspart protamine)

New Formulation Approved: August 26, 2008

FDA Approves Novolog Mix 50/50
 

New Drug Approvals Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Oct | Dec

More News Resources


MedNotes
Advertisement